AstraZeneca has launched in the UK a new pre-filled pen containing its once-weekly diabetes drug Bydureon (exenatide), offering patients a simpler route of administration. AstraZeneca has launched in ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

If you have type 2 diabetes, your doctor may recommend Bydureon BCise as a treatment. It’s used with a balanced diet and exercise to help manage blood sugar. Bydureon BCise is used in adults and ...

AstraZeneca has received regulatory approval for a single-use pen injector to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence rates and a huge unmet ...

AstraZeneca ($AZN) won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The ...

US regulators have given the thumbs-up to AstraZeneca's pre-filled, single-use pen injector version of its long-acting diabetes drug Bydureon. US regulators have given the thumbs-up to AstraZeneca’s ...

SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results ...

WILMINGTON, Del. -- AstraZeneca has received regulatory approval for a single-use pen injector designed to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence ...

As it approaches the end of a distinguished run, AstraZeneca’s type 2 diabetes franchise is showing its age. Sales are in decline for Byetta and Bydureon as they’ve been squeezed by formidable foes in ...

AstraZeneca expects to dominate the women’s cancer segment with PARP inhibitor, Lynparza. Increasing demand for SGLT2 diabetes drug, Farxiga, will be major growth driver for AstraZeneca. Once-a-week ...